Test Description

Pharmacology

Lithium is a monovalent cation (Li+) used primarily for bipolar disorder. It is entirely renally eliminated with no protein binding and a small volume of distribution (0.6-0.9 L/kg) initially, though it slowly enters cells over hours. The kidney handles lithium similarly to sodium — conditions that cause sodium reabsorption (volume depletion, diuretics) will also increase lithium reabsorption and raise levels.

Why Timing Matters

Lithium distributes slowly from the blood into tissues (especially the CNS). In acute ingestion, serum levels may be very high while tissue levels are still low — the patient may look relatively well despite alarming numbers. In chronic toxicity, tissue levels have equilibrated and even modest serum elevations can produce severe neurotoxicity.

A serum lithium level of 2.5 mEq/L in a patient on chronic lithium therapy is far more dangerous than the same level in an acute, naive ingestion. Always determine whether this is acute, chronic, or acute-on-chronic toxicity — the clinical approach differs significantly.
Quick Reference
  • Therapeutic Range: 0.6 – 1.2 mEq/L (some references accept 0.8 – 1.2 for acute bipolar episodes)
  • Mild Toxicity: 1.5 – 2.5 mEq/L
  • Moderate Toxicity: 2.5 – 3.5 mEq/L
  • Severe/Life-Threatening: >3.5 mEq/L
  • Key Point: Chronic toxicity is MORE dangerous than acute ingestion — patients can develop severe neurotoxicity at lower levels
  • Treatment: Aggressive IV normal saline; hemodialysis for severe or refractory toxicity
  • Elimination: 100% renal (no hepatic metabolism); handled like sodium by the kidney
  • Sample Timing: Draw trough level 12 hours post-dose; 8-12 hours after last dose minimum
Reference Ranges & Toxicity Levels
Swipe to see more
Level (mEq/L) Classification Expected Clinical Findings
0.6 – 1.2 Therapeutic Fine tremor, mild polyuria/polydipsia may occur at therapeutic levels
1.5 – 2.5 Mild Toxicity Coarse tremor, nausea, vomiting, diarrhea, lethargy, difficulty concentrating
2.5 – 3.5 Moderate Toxicity Confusion, agitation, hyperreflexia, clonus, myoclonus, nystagmus, ataxia
>3.5 Severe Toxicity Seizures, coma, cardiovascular collapse, renal failure; may be fatal
These cutoffs apply primarily to chronic toxicity. In acute ingestion of a naive patient, levels >4 mEq/L may present with only GI symptoms. In chronic toxicity, severe neurotoxicity can occur at levels <2.5 mEq/L.
Acute vs. Chronic Toxicity
Swipe to see more
Feature Acute Ingestion Chronic Toxicity Acute-on-Chronic
Patient Not on lithium; intentional OD or accidental Chronic lithium user; precipitated by volume depletion, drug interaction, or renal change Chronic user who takes extra doses or has new precipitant
Serum Level May be very high (>4-6 mEq/L) May be only mildly elevated (1.5-3.0) Variable
Primary Symptoms GI predominant (nausea, vomiting, diarrhea) Neurologic predominant (tremor, confusion, ataxia, seizures) Mixed GI and neurologic
Danger Level Less dangerous — tissues have not yet equilibrated Most dangerous — CNS tissue levels are high Intermediate; depends on chronicity
Rebound After HD Common (redistribution from GI tract/tissues) Less common but possible Possible

Common Triggers of Chronic Toxicity

  • Volume depletion — fever, vomiting, diarrhea, poor oral intake, excessive sweating
  • NSAIDs — decrease renal lithium clearance by 15-25%
  • ACE inhibitors / ARBs — decrease lithium clearance
  • Thiazide diuretics — increase proximal tubule sodium (and lithium) reabsorption
  • Acute kidney injury — from any cause
  • Low-sodium diet — increased proximal reabsorption of lithium
The most common scenario: An elderly patient on chronic lithium develops gastroenteritis or starts an NSAID/ACE inhibitor, becomes volume-depleted, and presents with confusion, tremor, and a lithium level of 2.0 mEq/L. This is chronic toxicity and is a medical emergency.
Treatment & Hemodialysis

General Management

  1. Stop lithium immediately
  2. Aggressive IV normal saline — cornerstone of treatment; restores GFR and promotes renal lithium excretion. Avoid lactated Ringer's. Goal: establish euvolemia then continue generous hydration.
  3. Whole bowel irrigation (WBI) — for acute ingestions, especially sustained-release formulations; polyethylene glycol (GoLYTELY) 1-2 L/hour until clear rectal effluent
  4. Activated charcoal is NOT effective — lithium is a monovalent cation and is not adsorbed by charcoal
  5. Serial lithium levels — every 2-4 hours (levels can rise after acute ingestion as absorption continues, especially with sustained-release)
  6. Monitor electrolytes, renal function, ECG

Hemodialysis Indications (EXTRIP Guidelines)

  • Lithium level >5.0 mEq/L regardless of symptoms
  • Lithium level >4.0 mEq/L with impaired kidney function (eGFR <45) or clinical toxicity
  • Altered mental status, seizures, or life-threatening dysrhythmias regardless of level
  • Clinical deterioration despite aggressive supportive care
  • Renal failure preventing clearance

HD Practical Notes

  • Lithium is an ideal candidate for HD: small molecule, no protein binding, low Vd, water-soluble
  • Typical HD run: 4-6 hours minimum; may need prolonged or repeated sessions
  • Rebound: Lithium redistribution from tissues back into blood occurs post-HD. Check level 6 hours after HD — if >1.0 mEq/L, repeat HD
  • Continuous renal replacement therapy (CRRT) can be used if hemodynamically unstable, but clears lithium more slowly than intermittent HD
Continue HD until lithium level <1.0 mEq/L and recheck 6-8 hours post-HD for rebound. Acute ingestions are more prone to rebound due to delayed absorption from the GI tract and redistribution.
Clinical Pearls
SILENT syndrome (Syndrome of Irreversible Lithium-Effectuated Neurotoxicity): Persistent neurologic deficits (cerebellar dysfunction, cognitive impairment, extrapyramidal symptoms) that remain after lithium is cleared. Most common after chronic toxicity. The damage is irreversible — this is why chronic lithium toxicity is treated more aggressively than acute ingestion.
Activated charcoal is useless for lithium — lithium is a small monovalent cation not adsorbed by charcoal. Whole bowel irrigation with polyethylene glycol is the decontamination method of choice for large acute ingestions, especially sustained-release formulations.
Nephrogenic diabetes insipidus (NDI): Chronic lithium use causes NDI in up to 40% of patients (lithium inhibits ADH-mediated aquaporin-2 insertion). Patients present with polyuria and polydipsia. Paradoxically, amiloride (a K+-sparing diuretic) is the treatment of choice — it blocks lithium entry into collecting duct cells.
Check a pregnancy test in reproductive-age women: Lithium is teratogenic (Ebstein anomaly — tricuspid valve displacement). Always check pregnancy status in women of childbearing age presenting with lithium toxicity, as management decisions may be affected.
Sustained-release lithium formulations can cause delayed and prolonged absorption. A serum level that appears to be trending down may rise again. Continue monitoring for at least 24 hours after acute ingestion of sustained-release products, and consider WBI aggressively.
References
  1. Baird-Gunning, J., Lea-Henry, T., Hoegberg, L. C., Gosselin, S., & Roberts, D. M. (2017). Lithium poisoning. Journal of Intensive Care Medicine, 32(4), 249-263.
  2. Decker, B. S., Goldfarb, D. S., Dargan, P. I., et al. (2015). Extracorporeal treatment for lithium poisoning: systematic review and recommendations from the EXTRIP workgroup. Clinical Journal of the American Society of Nephrology, 10(5), 875-887.
  3. Adityanjee, Munshi, K. R., & Thampy, A. (2005). The syndrome of irreversible lithium-effectuated neurotoxicity. Clinical Neuropharmacology, 28(1), 38-49.
  4. Timmer, R. T., & Sands, J. M. (1999). Lithium intoxication. Journal of the American Society of Nephrology, 10(3), 666-674.
  5. Nelson, L. S., Howland, M. A., Lewin, N. A., et al. (Eds.). (2019). Goldfrank's Toxicologic Emergencies (11th ed.). McGraw-Hill. Chapter: Lithium.
Back to Toxicology Panel All Lab Values
Medical Disclaimer
  • For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
  • Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
  • Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
The clinical content and references are curated and reviewed by myself; however, AI was used to assist in organizing, paraphrasing, and formatting the information presented.